Article Dans Une Revue ACS Infectious Diseases Année : 2025

Reductive Activation of Artefenomel (OZ439) by Fe(II)-Heme, Related to Its Antimalarial Activity

Résumé

The 1,2,4-trioxolane antimalarial drug, OZ439 (artefenomel), exhibits cross-resistance to artemisinins in vitro with similar survival rates of artemisinin-resistant parasites after dihydroartemisinin or OZ439 exposure, suggesting that this drug shares some mechanisms of action with artemisinins. In this way, we investigated the in vitro reductive activation of OZ439 by heme in the presence of dithionite, demonstrating the formation of covalent heme-drug adducts. However, in the presence of the biologically abundant reductant glutathione instead of dithionite, heme-drug adducts were not detected, contrary to artemisinin that efficiently alkylates heme regardless of the reductant used. Conversely, the C-centered radical of OZ439 resulting from heme-mediated activation of the drug reacts with the thiol function of glutathione, thus confirming the ability of this drug to alkylate proteins or other biological targets. So, the difference in the mechanism of action between artemisinin and OZ439 in vivo may rely on the different proportions between heme alkylation and protein alkylation.
Fichier sous embargo
Fichier sous embargo
0 4 11
Année Mois Jours
Avant la publication
lundi 16 juin 2025
Fichier sous embargo
lundi 16 juin 2025
Connectez-vous pour demander l'accès au fichier

Dates et versions

hal-04928043 , version 1 (05-02-2025)

Identifiants

Citer

Michel Nguyen, Lucie Paloque, Jeanne Manaranche, Mickaël Chabbert, Alexandre Hamouy, et al.. Reductive Activation of Artefenomel (OZ439) by Fe(II)-Heme, Related to Its Antimalarial Activity. ACS Infectious Diseases, 2025, 11 (1), pp.216-225. ⟨10.1021/acsinfecdis.4c00787⟩. ⟨hal-04928043⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More